eligibility_summary
Eligibility: 18–75 yrs with confirmed cHL, ECOG 0–1, ≥2 prior therapies (transplant-ineligible/refused), life expectancy ≥3 mo, ≥1 measurable lesion >1 cm, prior therapy >4 wks ago with ≤grade 1 toxicity, autologous HSCT allowed if >3 mo, adequate marrow/liver/renal/heart. Exclude prior PD‑1 combos (chidamide+decitabine or BV+bendamustine), autoimmune needing immunosuppression/steroids, serious uncontrolled illness or active infection (esp pulmonary), active/recent (≤1 mo) GI bleed, organ allograft, pregnancy/breastfeeding/positive test, or compulsory detention.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 randomized trial in transplant-ineligible/refused R/R classical Hodgkin lymphoma comparing: 1) Chidamide (oral benzamide-class HDAC1/2/3/10 inhibitor, epigenetic reprogramming to induce tumor apoptosis and enhance immune surveillance) + Decitabine (hypomethylating DNMT1 inhibitor, increases tumor antigen/HLA expression, antigen processing, and T-cell infiltration/function) + anti-PD-1 antibody (immune checkpoint inhibitor restoring T-cell activation) versus 2) Brentuximab vedotin (CD30-directed antibody-drug conjugate delivering MMAE to disrupt microtubules in Reed-Sternberg cells) + Bendamustine (alkylating agent causing DNA crosslinks) + anti-PD-1. Targets/pathways: HDACs, DNMT1/DNA methylation and antigen presentation, PD-1/PD-L1 on T cells, CD30 on Hodgkin cells, microtubules, DNA crosslink/repair. Primary endpoint: PFS.